For the second quarter of 2026, Biomea Fusion is expected to report a loss per share of $0.21 on zero revenue, with the current stock price of $1.17 trading significantly below the average analyst price target of $8.50.
Investors are primarily focused on clinical progress for the lead candidate icovamenib (BMF-219), specifically seeking updates from the Phase II COVALENT-212 trial in Type 2 Diabetes.
The company has recently pivoted to prioritize its metabolic disease pipeline, terminating its Type 1 Diabetes program to preserve resources. Management’s guidance on cash runway, currently projected into early 2027, and results from ongoing obesity studies will be essential for rebuilding investor confidence.